Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2019

Oct 30, 2019

SELL
$120.61 - $148.29 $18,091 - $22,243
-150 Closed
0 $0
Q2 2019

Aug 09, 2019

BUY
$113.99 - $146.86 $11,399 - $14,686
100 Added 200.0%
150 $18,000
Q4 2018

Feb 01, 2019

BUY
$107.01 - $175.15 $5,350 - $8,757
50 New
50 $7,000

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $22.7B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Essex Savings Bank Portfolio

Follow Essex Savings Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Essex Savings Bank, based on Form 13F filings with the SEC.

News

Stay updated on Essex Savings Bank with notifications on news.